Related Experiment Video

Updated: Jun 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

Robin L Jones1, David Olmos, Khin Thway

  • 1Royal Marsden Hospital, London, SW3 6JJ, UK. rjones@seattlecca.org

Cancer Chemotherapy and Pharmacology
|November 12, 2010
PubMed
Abstract

Insights

Phase I clinical trials offer a valuable therapeutic option for advanced sarcoma patients lacking standard treatments. These trials demonstrate potential clinical benefit with manageable toxicity, providing a crucial pathway for further care.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Sarcoma Research

Background:

  • Standard systemic treatments for advanced sarcoma are limited, often involving doxorubicin, ifosfamide, or trabectedin.
  • Patients progressing on conventional therapies may be offered experimental options like Phase I clinical trials.

Purpose of the Study:

  • To evaluate the clinical benefit of Phase I clinical trials for sarcoma patients.
  • To assess the response, toxicity, and outcomes in sarcoma patients treated within a Phase I Unit.

Main Methods:

  • Analysis of sarcoma patients treated in Phase I clinical trials at a single referral center.
  • Data collection spanned from August 1998 to December 2010, including response, toxicity, and survival outcomes.

Main Results:

  • 133 patients with a median of 3 prior systemic therapies were treated.
  • Objective response rates were low (1.6% partial response), but 3-month non-progression rate was 31.5%.
  • Median progression-free survival was 2.1 months, median overall survival was 7.6 months, with 18.0% experiencing grade 3/4 toxicity.

Conclusions:

  • Phase I clinical trials represent a viable therapeutic option for sarcoma patients with no remaining standard treatment options.
  • The potential for clinical benefit and relatively low toxicity risk support their consideration in advanced sarcoma management.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...